Refine by
Dna Rna Target Articles & Analysis
13 news found
The field of protein DNA/RNA interactions is an expanding area of research. These interactions affect fundamental processes and as a result, relevant protein DNA/RNA processing complexes and their associated mechanisms provide interesting therapeutic targets to researchers. ...
The data were communicated at ASCO 2022 last week and showed that Artificial Intelligence RNA-based therapeutic recommendations have the potential to expand personalized cancer treatment options for patients with advanced & refractory diseases. Focusing on a cohort of advanced & refractory cancer patients without tractable DNA alterations, the analysis ...
VITRUVIAN BioMedical, Inc. (“VITRUVIAN”), a biotechnology company, today announced obtaining the Exclusive License for a new Therapeutic Vaccine for Alzheimer’s Disease (AD) from Dr. Yoh Matsumoto from the Immunotherapy Development Inc. in Saitama, Japan and the Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan. The AD Vaccine, YM7555, is a DNA Vaccine that targets ...
ViGeneron announces follow-on collaboration with Daiichi Sankyo to develop a novel gene therapy for prevalent eye diseases The companies agree a follow-on collaboration to evaluate ViGeneron’s adeno-associated virus vectors (vgAAVs) for delivering Daiichi Sankyo’s novel therapeutic protein to treat prevalent eye diseases ViGeneron GmbH, a next-generation gene therapy company, ...
Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™ software, the leading solution for visualization, interpretation and reporting of genomic data, today announced the launch of an integrated genomic scar analysis for homologous recombination deficiency (HRD) in the version 6.2 software release of NxClinical. ...
Eligo Bioscience SA, a Paris, France-based microbiome engineering company, today announced that the Company presented preclinical data on its lead drug candidate, EB003, for the treatment of severe diarrhea induced by shiga-toxin (Stx) producing E. coli (STEC, leading to Hemolytic Uremic Syndrome), at the 14th Annual CRISPR 2021 meeting held June 1-10, 2021. The data presented further supports ...
Creative Enzymes, a professional enzyme provider located in New York, always hammers at researches and trials in order to provide customers with various enzyme products and services as many as possible. Creative Enzymes has recently launched Tn5 Transposase for researchers. With more than ten-year experience in offering professional services and high-quality products for academic use and ...
The new panel enables simultaneous analysis of DNA mutations and RNA fusion transcripts in myeloid samples in a single day. It also provides researchers the ability to profile 40 DNA targets and 29 fusion driver genes, enabling detection of more than 600 fusion isotypes to identify biomarkers associated with myeloproliferative ...
Genome Canada, the Ontario Institute for Cancer Research (OICR) and Thermo Fisher Scientific are collaborating to develop a complete solution of targeted next generation sequencing (NGS) assays and analysis software designed to more effectively assess – and eventually improve management of – pancreatic, prostate and breast cancer. ...
In the simplest of terms, DNA, or deoxyribonucleic acid, is the genetic code that determines all the characteristics of a living thing. This double, long chain of molecules called nucleotides tell each cell what proteins to make, giving them the genetic instruction guide for life and its processes. Each cell’s development, reproduction and death are controlled by the ...
Agilent Technologies Inc. (NYSE: A) today introduced the new SureDirect Blood PCR Kit for amplification of DNA directly from blood and blood derivatives, without the need for nucleic acid extraction and isolation. This kit simplifies the DNA amplification workflow and decreases turn-around time by enabling PCR (polymerase chain reaction) directly from fresh, frozen and dried blood, as well as ...
Agilent Technologies Inc. (NYSE: A) today introduced a new SureSelect target enrichment solution that allows Ion Proton users to realize the full power of their next-generation sequencers with the industry's leading human exome and custom DNA target enrichment solutions. SureSelect target enrichment is now available for all major sequencing platforms, enabling researchers to achieve the ...
Agilent Technologies, Inc., (NYSE: A) today introduced SureSelect RNA Capture Kits, the first commercial RNA target enrichment system enabling geneticists to focus on specific genomic loci or transcripts of research interest. ...